HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch

This article was originally published in The Rose Sheet

Executive Summary

Jim O'Neill, a Silicon Valley investment manager, would be an unusual choice to head FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, who worked at HHS in the Bush administration, others suggest he could champion much-needed change at the agency.

You may also be interested in...



FDA Commish Nominee Could Be Mixed Blessing For Cosmetics Industry

Physician and former FDA official Scott Gottlieb, nominated by President Trump to head up the agency, is a more conventional pick for the role than other reportedly short-listed individuals. His science background checks a box on the cosmetics industry’s wish list, but he also – like Trump – has been a proponent of cutting red tape, while cosmetics players are actually seeking more involved federal oversight.

Trump Meets With Two FDA Commissioner Candidates; Third Still In Play

O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.

Will US FDA Wind Up With More Political Positions Under Trump?

Incoming administration could appoint key legal and policy positions to shape agenda’s agenda.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel